Health News

Zydus launches Topiramate Extended-Release Capsules for epilepsy

Ahmedabad: Zydus Pharmaceuticals (USA) Inc. (Zydus), a subsidiary of Zydus Lifesciences Limited (formerly Cadila Healthcare Limitedhas launched Topiramate Extended-Release Capsules,

The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release capsules, USP 25 mg, 50 mg, and 100 mg (USRLD: Trokendi XR, Zydus is the first company to receive final approval and launch Topiramate Extended-Release capsules, USP 25 mg, 50 mg, and 100 mg in the United States.

Topiramate Extended-Release Capsule is indicated for epilepsy in two ways: as an initial monotherapy for patients six years of age and older who have partial onset or primary generalized tonic-clonic seizures, and as an adjunctive therapy for patients who suffer from these types of seizures or seizures linked to Lenox-Gastaut Syndrome (LGS), Additionally, it is approved for people 12 years of age and older who are at risk for migraines,

According to IQVIA data, Topiramate Extended-Release Capsule had annual sales of USD 488 million in the United States (IQVIA MAT Nov. 2022).

Follow and connect with us on , facebook, LinkedIn, youtube




Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button